Meeting
2015 Genitourinary Cancers Symposium
Prognostic biomarker exploration for patients with metastatic renal cell carcinoma receiving VEGFR TKI.
Authors
Inkeun Park
Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea
Inkeun Park , Yong Mee Cho , Jae-Lyun Lee , Jin-Hee Ahn , Dae Ho Lee , Dalsan You , In Gab Jeong , Cheryn Song , Bum-Sik Hong , Jun Hyuck Hong , Hanjong Ahn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 491)
DOI
10.1200/jco.2015.33.7_suppl.491
Abstract #
491
Poster Bd #
G19
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI).
First Author: Margaret von Mehren
Poster
2018 Genitourinary Cancers Symposium
A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.
First Author: Ilya Tsimafeyeu
Poster
2017 Genitourinary Cancers Symposium
Second line axitinib in metastatic renal cell carcinoma: Evaluation of prognostic factors influencing outcome.
First Author: Helen Brooks
Poster
2016 Genitourinary Cancers Symposium
Real world chart review of adverse event management in patients taking tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC) by line of therapy (LoT).
First Author: Sandhya Srinivas